Skip to NavigationSkip to content

trial failure

AstraZeneca’s selumetinib fails to meet primary endpoint in lung cancer trial again

AstraZeneca has announced that its MEK 1/2 inhibitor, selumetinib, failed to meet its primary endpoint of progression free survival in patients with KRAS mutation-positive locally-advanced or metastatic non-small cell lung cancer.

The drug candidate failed to meet its primary endpoint in a 2011 Phase II trial in the same indication. In both trials, selutmetinib was used in combination with Sanofi chemotherapy drug Taxotere (docetaxel) as a 2nd line treatment.

Phase II failure sees stock plunge and job cutbacks for Infinity Pharmaceuticals

Shares at Infinity Pharmaceuticals (NASDAQ: INFI) fell around 70% upon the announcement of new Phase II data for their non-Hodgkin lymphoma monotherapy, duvelisib.

The investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma was being developed by Infinity, in partnership with AbbVie. The Phase II DYNAMO trial met its primary endpoint of overall response rate, with 46%, but all of these were partial responses.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches